JP6106854B2 - ＦｃＲｎに対する抗体及びその使用 - Google Patents

ＦｃＲｎに対する抗体及びその使用 Download PDF

Info

Publication number
JP6106854B2
JP6106854B2 JP2011506301A JP2011506301A JP6106854B2 JP 6106854 B2 JP6106854 B2 JP 6106854B2 JP 2011506301 A JP2011506301 A JP 2011506301A JP 2011506301 A JP2011506301 A JP 2011506301A JP 6106854 B2 JP6106854 B2 JP 6106854B2
Authority
JP
Japan
Prior art keywords
antibody
fcrn
binding
antibodies
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2011506301A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011523351A (ja
JP2011523351A5 (enExample
Inventor
テンホー，クリストファー
ムルガナンダム，アルムガン
ラドナー，ロバート，チャールズ
ウッド，クリーヴ
ビトンティ，アラン，ジェー．
シュタテル，ジェームズ
マクドネル，ケヴィン
リウ，リミン
デュモント，ジェニファー
サトウ，アーロン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Dyax Corp
Original Assignee
Dyax Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dyax Corp filed Critical Dyax Corp
Publication of JP2011523351A publication Critical patent/JP2011523351A/ja
Publication of JP2011523351A5 publication Critical patent/JP2011523351A5/ja
Application granted granted Critical
Publication of JP6106854B2 publication Critical patent/JP6106854B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/283—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
    • A61K49/0058—Antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/14—Peptides, e.g. proteins
    • A61K49/16—Antibodies; Immunoglobulins; Fragments thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1027—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against receptors, cell-surface antigens or cell-surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
    • G01N2333/70535—Fc-receptors, e.g. CD16, CD32, CD64 (CD2314/705F)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Plant Pathology (AREA)
  • Optics & Photonics (AREA)
  • Radiology & Medical Imaging (AREA)
JP2011506301A 2008-04-25 2009-04-24 ＦｃＲｎに対する抗体及びその使用 Active JP6106854B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US4815208P 2008-04-25 2008-04-25
US61/048,152 2008-04-25
US4850008P 2008-04-28 2008-04-28
US61/048,500 2008-04-28
PCT/US2009/002536 WO2009131702A2 (en) 2008-04-25 2009-04-24 Antibodies against fcrn and use thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2015027638A Division JP5989159B2 (ja) 2008-04-25 2015-02-16 ＦｃＲｎに対する抗体及びその使用

Publications (3)

Publication Number Publication Date
JP2011523351A JP2011523351A (ja) 2011-08-11
JP2011523351A5 JP2011523351A5 (enExample) 2012-06-07
JP6106854B2 true JP6106854B2 (ja) 2017-04-05

Family

ID=41203902

Family Applications (5)

Application Number Title Priority Date Filing Date
JP2011506301A Active JP6106854B2 (ja) 2008-04-25 2009-04-24 ＦｃＲｎに対する抗体及びその使用
JP2015027638A Active JP5989159B2 (ja) 2008-04-25 2015-02-16 ＦｃＲｎに対する抗体及びその使用
JP2016155218A Active JP6499132B2 (ja) 2008-04-25 2016-08-08 ＦｃＲｎに対する抗体及びその使用
JP2019046955A Pending JP2019162105A (ja) 2008-04-25 2019-03-14 ＦｃＲｎに対する抗体及びその使用
JP2022075914A Pending JP2022115960A (ja) 2008-04-25 2022-05-02 ＦｃＲｎに対する抗体及びその使用

Family Applications After (4)

Application Number Title Priority Date Filing Date
JP2015027638A Active JP5989159B2 (ja) 2008-04-25 2015-02-16 ＦｃＲｎに対する抗体及びその使用
JP2016155218A Active JP6499132B2 (ja) 2008-04-25 2016-08-08 ＦｃＲｎに対する抗体及びその使用
JP2019046955A Pending JP2019162105A (ja) 2008-04-25 2019-03-14 ＦｃＲｎに対する抗体及びその使用
JP2022075914A Pending JP2022115960A (ja) 2008-04-25 2022-05-02 ＦｃＲｎに対する抗体及びその使用

Country Status (17)

Country Link
US (10) US8273351B2 (enExample)
EP (3) EP3348573B1 (enExample)
JP (5) JP6106854B2 (enExample)
KR (4) KR101837329B1 (enExample)
CN (3) CN108467431A (enExample)
AU (1) AU2009238605B2 (enExample)
BR (2) BRPI0910622A2 (enExample)
CA (2) CA2722082C (enExample)
ES (1) ES2650804T3 (enExample)
HK (1) HK1207089A1 (enExample)
IL (2) IL208846A (enExample)
MX (1) MX2010011679A (enExample)
NZ (1) NZ589451A (enExample)
SG (3) SG10201804513WA (enExample)
TW (3) TWI453031B (enExample)
WO (1) WO2009131702A2 (enExample)
ZA (1) ZA201007873B (enExample)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8273351B2 (en) * 2008-04-25 2012-09-25 Dyax Corp. Fc receptor binding proteins
SG10201609665PA (en) 2011-02-25 2017-01-27 Chugai Pharmaceutical Co Ltd FcɣRIIb-SPECIFIC Fc ANTIBODY
BR112013030352B1 (pt) * 2011-06-02 2020-05-19 Dyax Corp. anticorpo anti-fcrn isolado, composição farmacêutica que compreende o dito anticorpo, ácido nucleico isolado, vetor, célula e uso terapêutico do dito anticorpo
WO2013002362A1 (ja) 2011-06-30 2013-01-03 中外製薬株式会社 ヘテロ二量化ポリペプチド
CN107287660A (zh) * 2011-09-30 2017-10-24 中外制药株式会社 离子浓度依赖性结合分子文库
JP6322411B2 (ja) 2011-09-30 2018-05-09 中外製薬株式会社 複数の生理活性を有する抗原の消失を促進する抗原結合分子
KR20210074395A (ko) 2011-11-30 2021-06-21 추가이 세이야쿠 가부시키가이샤 면역 복합체를 형성하는 세포내로의 운반체（캐리어）를 포함하는 의약
CA2865158C (en) 2012-02-24 2022-11-01 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule for promoting disappearance of antigen via fc.gamma.riib
JP5855239B2 (ja) 2012-04-23 2016-02-09 株式会社Ｎｒｌファーマ ラクトフェリン融合タンパク質及びその製造方法
GB201208370D0 (en) 2012-05-14 2012-06-27 Ucb Pharma Sa Antibodies
JP6284548B2 (ja) * 2012-12-21 2018-02-28 バイオジェン・エムエイ・インコーポレイテッドＢｉｏｇｅｎ ＭＡ Ｉｎｃ． ヒト抗タウ抗体
MX366425B (es) * 2013-03-15 2019-07-04 Affibody Ab Nuevos polipeptidos.
ZA201506407B (en) * 2013-03-15 2018-11-28 Affibody Ab New polypeptides
SG11201508170TA (en) 2013-04-02 2015-11-27 Chugai Pharmaceutical Co Ltd Fc REGION VARIANT
US20160075766A1 (en) * 2013-05-21 2016-03-17 Roche Diagnostics Operations, Inc. Method for producing antibodies using ovine b-cells and uses thereof
JP2016531915A (ja) * 2013-08-28 2016-10-13 ステムセントリックス， インコーポレイテッド 部位特異的抗体コンジュゲーション方法および組成物
GB201320066D0 (en) * 2013-11-13 2013-12-25 Ucb Pharma Sa Biological products
CN106103476B (zh) * 2013-12-24 2020-11-27 阿尔金克斯有限公司 FcRn拮抗剂及使用方法
US20170045528A1 (en) * 2014-04-25 2017-02-16 The Brigham And Women's Hospital, Inc. Compositions and methods for treating subjects with immune-mediated diseases
US10336825B2 (en) 2014-04-30 2019-07-02 Hanall Biopharma Co., Ltd. Antibody binding to FcRn for treating autoimmune diseases
EP4241852A3 (en) 2014-04-30 2023-11-15 Hanall Biopharma Co., Ltd. Antibody binding to fcrn for treating autoimmune diseases
JP6568207B2 (ja) * 2014-05-19 2019-08-28 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ ヒツジｂ細胞を用いて抗体を産生するための方法およびその使用
US10323066B2 (en) 2014-09-17 2019-06-18 Affibody Ab Neonatal Fc receptor binding dimer and methods of use
MX2017005774A (es) 2014-12-19 2017-07-28 Chugai Pharmaceutical Co Ltd Anticuerpos antimiostatina, polipeptidos que contienen regiones fc variantes, y metodos de uso.
JP6853178B2 (ja) * 2015-01-30 2021-03-31 モメンタ ファーマシューティカルズ インコーポレイテッド ＦｃＲｎ抗体およびその使用方法
CN114773469B (zh) 2015-02-05 2025-12-19 中外制药株式会社 包含离子浓度依赖性的抗原结合结构域的抗体，fc区变体，il-8-结合抗体及其应用
CA3022547A1 (en) * 2015-05-12 2016-11-17 Syntimmune, Inc. Humanized affinity matured anti-fcrn antibodies
GB201508180D0 (en) * 2015-05-13 2015-06-24 Ucb Biopharma Sprl Antibodies
CA2996299C (en) 2015-08-24 2022-09-27 University Of Cincinnati Methods and compositions for the detection of fc receptor binding activity of antibodies
EP3394098A4 (en) 2015-12-25 2019-11-13 Chugai Seiyaku Kabushiki Kaisha ANTI-MYOSTATIN ANTIBODIES AND METHOD OF USE
CN106957365B (zh) * 2016-01-11 2021-03-16 上海交通大学 一种单克隆抗体FnAb8及其应用
US11542332B2 (en) 2016-03-26 2023-01-03 Bioatla, Inc. Anti-CTLA4 antibodies, antibody fragments, their immunoconjugates and uses thereof
BR112019001806A2 (pt) * 2016-07-29 2019-05-07 Momenta Pharmaceuticals, Inc. anticorpos para fcrn e métodos de uso dos mesmos
CN116271014A (zh) 2016-08-05 2023-06-23 中外制药株式会社 用于预防或治疗il-8相关疾病的组合物
EP3533870A4 (en) 2016-10-28 2020-04-08 NRL Pharma, Inc. LACTOFERRIN / ALBUMIN FUSION PROTEIN AND PROCESS FOR PRODUCING THE SAME
GB201618424D0 (en) * 2016-11-01 2016-12-14 Argenix Bvba Treatment of antibody mediated disease
MX2019015065A (es) * 2017-06-15 2020-08-03 UCB Biopharma SRL Metodo para tratamiento de trombocitopenia inmunitaria.
EP4640703A3 (en) 2017-11-14 2026-04-08 Chugai Seiyaku Kabushiki Kaisha Anti-c1s antibodies and methods of use
MA51032A (fr) 2017-12-08 2021-03-17 Argenx Bvba Utilisation d'antagonistes de fcrn pour le traitement de la myasthénie grave généralisée
BR112020011310A2 (pt) * 2017-12-13 2020-11-17 Momenta Pharmaceuticals, Inc. anticorpos contra fcrn e seus métodos de uso
JP7486437B2 (ja) 2018-06-08 2024-05-17 アルジェニクス ビーブイ 免疫性血小板減少症を治療する組成物及び方法
EA202190264A1 (ru) 2018-07-20 2021-05-20 Момента Фармасьютикалз, Инк. КОМПОЗИЦИИ АНТИТЕЛ ПРОТИВ FcRn
MX2021001431A (es) 2018-08-10 2021-05-12 Chugai Pharmaceutical Co Ltd Molecula de union al antigeno anti grupo de diferenciacion 137 (cd137) y su uso.
JP7518821B2 (ja) 2018-10-16 2024-07-18 ユーシービー バイオファルマ エスアールエル 重症筋無力症の治療方法
MX2021005048A (es) 2018-10-31 2021-09-08 Bioatla Inc Anticuerpos anti-ctla4, fragmentos de anticuerpos, sus inmunoconjugados y usos.
CA3137649A1 (en) 2019-05-15 2020-11-19 Chugai Seiyaku Kabushiki Kaisha An antigen-binding molecule, a pharmaceutical composition, and a method
BR112021024632A2 (pt) 2019-06-07 2022-01-18 Argenx Bvba Formulações farmacêuticas de inibidores de fcrn adequados para administração subcutânea
CA3148826A1 (en) * 2019-08-01 2021-02-04 Janssen Biotech, Inc. Fcrn antibodies and methods of use thereof
ES2992247T3 (es) 2020-01-08 2024-12-11 argenx BV Antagonistas del receptor de Fc neonatal humano (FcRn) para el tratamiento de trastornos del pénfigo
WO2021160116A1 (zh) * 2020-02-10 2021-08-19 北京拓界生物医药科技有限公司 抗FcRn抗体、其抗原结合片段及其医药用途
KR102507515B1 (ko) * 2020-08-26 2023-03-08 이화여자대학교 산학협력단 신규 항체 라이브러리 제조방법 및 이로부터 제조된 라이브러리
CN116234827B (zh) * 2021-09-03 2026-07-14 舒泰神（北京）生物制药股份有限公司 特异性识别FcRn的抗体及其应用
AU2023281650A1 (en) 2022-05-30 2024-10-17 Hanall Biopharma Co., Ltd. Anti-fcrn antibody or antigen binding fragment thereof with improved stability
KR20250037789A (ko) 2022-06-15 2025-03-18 아르젠엑스 비브이 Fcrn/항원-결합 분자 및 사용 방법
CN115645537A (zh) * 2022-10-25 2023-01-31 成都臻拓医药科技有限公司 FcRn抑制剂在制备抑制自身免疫性疾病复发的药物中的用途
CN116047054A (zh) * 2023-03-08 2023-05-02 江西赛基生物技术有限公司 用于检测血小板抗体的试剂盒及其制备方法和使用方法
IL328082A (en) * 2023-11-06 2026-06-01 Momenta Pharmaceuticals Inc Compositions and methods for treating rheumatoid arthritis
GB202318512D0 (en) * 2023-12-04 2024-01-17 argenx BV Methods of determining potency

Family Cites Families (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3940475A (en) 1970-06-11 1976-02-24 Biological Developments, Inc. Radioimmune method of assaying quantitatively for a hapten
US3867517A (en) 1971-12-21 1975-02-18 Abbott Lab Direct radioimmunoassay for antigens and their antibodies
US4289747A (en) 1978-12-26 1981-09-15 E-Y Laboratories, Inc. Immunological determination using lectin
DE2901218A1 (de) 1979-01-13 1980-07-17 Byk Gulden Lomberg Chem Fab Ung von theophyllin
US4634665A (en) 1980-02-25 1987-01-06 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US5179017A (en) 1980-02-25 1993-01-12 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4376110A (en) 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US5374548A (en) 1986-05-02 1994-12-20 Genentech, Inc. Methods and compositions for the attachment of proteins to liposomes using a glycophospholipid anchor
MX9203291A (es) 1985-06-26 1992-08-01 Liposome Co Inc Metodo para acoplamiento de liposomas.
US4868103A (en) 1986-02-19 1989-09-19 Enzo Biochem, Inc. Analyte detection by means of energy transfer
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
ATE81724T1 (de) 1987-11-09 1992-11-15 Becton Dickinson Co Verfahren zur analyse haematopoietischer zellen in einer probe.
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
DE68927933T2 (de) 1988-09-02 1997-08-14 Dyax Corp Herstellung und auswahl von rekombinantproteinen mit verschiedenen bindestellen
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5030002A (en) 1989-08-11 1991-07-09 Becton, Dickinson And Company Method and apparatus for sorting particles with a moving catcher tube
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
ES2139598T3 (es) 1990-07-10 2000-02-16 Medical Res Council Procedimientos para la produccion de miembros de parejas de union especifica.
IE76732B1 (en) 1990-08-07 1997-11-05 Becton Dickinson Co One step test for absolute counts
US5179107A (en) 1990-09-07 1993-01-12 Schering Corporation Antiviral quinolinone compounds
DE69129154T2 (de) 1990-12-03 1998-08-20 Genentech, Inc., South San Francisco, Calif. Verfahren zur anreicherung von proteinvarianten mit geänderten bindungseigenschaften
US5370901A (en) 1991-02-15 1994-12-06 Bracco International B.V. Compositions for increasing the image contrast in diagnostic investigations of the digestive tract of patients
DE69233697T2 (de) 1991-03-01 2008-01-24 Dyax Corp., Cambridge Verfahren zur Entwicklung von bindenden Mikroproteinen
PT100379B (pt) 1991-04-10 1999-01-29 Scripps Research Inst Bibliotecas de receptores heterodimericos usando fagomideos
EP0590058B1 (en) 1991-06-14 2003-11-26 Genentech, Inc. HUMANIZED Heregulin ANTIBODy
DE4122599C2 (de) 1991-07-08 1993-11-11 Deutsches Krebsforsch Phagemid zum Screenen von Antikörpern
EP0552108B1 (en) 1992-01-17 1999-11-10 Lakowicz, Joseph R. Energy transfer phase-modulation fluoro-immunoassay
SE9201984D0 (sv) 1992-06-29 1992-06-29 Pharmacia Biosensor Ab Improvement in optical assays
US5827690A (en) 1993-12-20 1998-10-27 Genzyme Transgenics Corporatiion Transgenic production of antibodies in milk
US6030613A (en) 1995-01-17 2000-02-29 The Brigham And Women's Hospital, Inc. Receptor specific transepithelial transport of therapeutics
US6086875A (en) 1995-01-17 2000-07-11 The Brigham And Women's Hospital, Inc. Receptor specific transepithelial transport of immunogens
CA2219361C (en) 1995-04-27 2012-02-28 Abgenix, Inc. Human antibodies derived from immunized xenomice
WO1996034096A1 (en) 1995-04-28 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice
CA2249195A1 (en) * 1996-03-18 1997-09-25 Board Of Regents, The University Of Texas System Immunoglobin-like domains with increased half lives
EP1972194A1 (en) 1996-12-03 2008-09-24 Amgen Fremont Inc. Transgenic mammals having human ig loci including plural vh and vk regions and antibodies produced therefrom
IL131016A (en) 1997-01-21 2004-12-15 Gen Hospital Corp Selection of proteins using RNA-protein blends
EP0983303B1 (en) 1997-05-21 2006-03-08 Biovation Limited Method for the production of non-immunogenic proteins
EP1068356B8 (en) 1998-04-03 2007-01-03 Adnexus Therapeutics, Inc. Addressable protein arrays
GB9809951D0 (en) 1998-05-08 1998-07-08 Univ Cambridge Tech Binding molecules
AU776910B2 (en) 1998-12-08 2004-09-23 Merck Patent Gesellschaft Mit Beschrankter Haftung Modifying protein immunogenicity
US6472147B1 (en) 1999-05-25 2002-10-29 The Scripps Research Institute Methods for display of heterodimeric proteins on filamentous phage using pVII and pIX, compositions, vectors and combinatorial libraries
GB9928787D0 (en) 1999-12-03 2000-02-02 Medical Res Council Direct screening method
US6960178B2 (en) 2000-02-02 2005-11-01 Xepmed, Inc. Apparatus for enhanced plasmapheresis and methods thereof
WO2002043658A2 (en) 2000-11-06 2002-06-06 The Jackson Laboratory Fcrn-based therapeutics for the treatment of auto-immune disorders
US20030186374A1 (en) 2001-10-01 2003-10-02 Hufton Simon E. Multi-chain eukaryotic display vectors and uses thereof
US20040005709A1 (en) 2001-10-24 2004-01-08 Hoogenboom Henricus Renerus Jacobus Mattheus Hybridization control of sequence variation
US7662928B2 (en) * 2003-08-08 2010-02-16 The Research Foundation Of State University Of New York Anti-FcRn antibodies for treatment of auto/allo immune conditions
CA2534973A1 (en) 2003-08-08 2005-02-17 The Research Foundation Of State University Of New York Anti-fcrn antibodies for treatment of auto/allo immune conditions
JP2008538919A (ja) * 2005-04-29 2008-11-13 ザ ジャクソン ラボラトリー ＦｃＲｎ抗体およびその使用
US20090092507A1 (en) * 2005-08-05 2009-04-09 Ramirez Jr Emilio A Fluid pump systems
CA2637929A1 (en) * 2006-01-25 2007-08-02 The Research Foundation Of State University Of New York Anti-fcrn antibodies for treatement of auto/allo immune conditions
US8359965B2 (en) 2007-09-17 2013-01-29 Oxford J Craig Apparatus and method for broad spectrum radiation attenuation
ES2687808T3 (es) 2007-09-26 2018-10-29 Chugai Seiyaku Kabushiki Kaisha Región constante de anticuerpo modificado
AR068723A1 (es) 2007-10-05 2009-12-02 Glaxo Group Ltd Proteina que se une a antigenos que se une a il-23 humana y sus usos
US8273351B2 (en) * 2008-04-25 2012-09-25 Dyax Corp. Fc receptor binding proteins
BR112013030352B1 (pt) * 2011-06-02 2020-05-19 Dyax Corp. anticorpo anti-fcrn isolado, composição farmacêutica que compreende o dito anticorpo, ácido nucleico isolado, vetor, célula e uso terapêutico do dito anticorpo
MA51032A (fr) * 2017-12-08 2021-03-17 Argenx Bvba Utilisation d'antagonistes de fcrn pour le traitement de la myasthénie grave généralisée
JP7486437B2 (ja) * 2018-06-08 2024-05-17 アルジェニクス ビーブイ 免疫性血小板減少症を治療する組成物及び方法
EP3969125A4 (en) * 2019-05-17 2023-01-11 Alexion Pharmaceuticals, Inc. USE OF ANTI-FCRN ANTIBODIES IN THE TREATMENT OF PEMPHIGHUS AND PEMPHIGOID DISEASES

Also Published As

Publication number Publication date
JP2011523351A (ja) 2011-08-11
CN102149729B (zh) 2014-08-20
TW201509430A (zh) 2015-03-16
US20160222112A1 (en) 2016-08-04
WO2009131702A9 (en) 2010-09-23
AU2009238605A1 (en) 2009-10-29
NZ589451A (en) 2012-07-27
US20160194397A1 (en) 2016-07-07
US9260520B2 (en) 2016-02-16
SG10201804513WA (en) 2018-07-30
TWI593423B (zh) 2017-08-01
EP3670538A1 (en) 2020-06-24
EP2310415B1 (en) 2017-10-11
IL241091B (en) 2018-02-28
US20140248287A1 (en) 2014-09-04
CA2722082C (en) 2021-11-09
WO2009131702A2 (en) 2009-10-29
ZA201007873B (en) 2012-02-29
SG10202105499WA (en) 2021-07-29
CN108467431A (zh) 2018-08-31
SG196839A1 (en) 2014-02-13
AU2009238605B2 (en) 2014-11-06
BR122021026834B1 (pt) 2022-11-08
KR20190104432A (ko) 2019-09-09
JP2019162105A (ja) 2019-09-26
US20160222109A1 (en) 2016-08-04
IL208846A (en) 2015-09-24
CN104479017A (zh) 2015-04-01
KR20160079912A (ko) 2016-07-06
BRPI0910622A2 (pt) 2020-03-10
US20160222108A1 (en) 2016-08-04
CA3131470A1 (en) 2009-10-29
KR20110044729A (ko) 2011-04-29
US20160222111A1 (en) 2016-08-04
TW201010720A (en) 2010-03-16
MX2010011679A (es) 2011-05-23
JP6499132B2 (ja) 2019-04-10
CN102149729A (zh) 2011-08-10
IL208846A0 (en) 2011-01-31
KR101634719B1 (ko) 2016-06-29
WO2009131702A3 (en) 2010-02-18
US8815246B2 (en) 2014-08-26
US20160222110A1 (en) 2016-08-04
JP2015143230A (ja) 2015-08-06
EP3348573A1 (en) 2018-07-18
ES2650804T3 (es) 2018-01-22
EP3348573B1 (en) 2020-04-22
CA2722082A1 (en) 2009-10-29
KR102072896B1 (ko) 2020-02-03
KR101837329B1 (ko) 2018-03-09
JP2022115960A (ja) 2022-08-09
TWI547287B (zh) 2016-09-01
US20130045218A1 (en) 2013-02-21
KR20170122286A (ko) 2017-11-03
IL241091A0 (en) 2015-11-30
JP2017029149A (ja) 2017-02-09
US8273351B2 (en) 2012-09-25
EP2310415B8 (en) 2017-12-13
TW201630626A (zh) 2016-09-01
US20130078262A1 (en) 2013-03-28
TWI453031B (zh) 2014-09-21
JP5989159B2 (ja) 2016-09-07
HK1207089A1 (en) 2016-01-22
EP2310415A2 (en) 2011-04-20
HK1160868A1 (en) 2012-08-17
US20090324614A1 (en) 2009-12-31

Similar Documents

Publication Publication Date Title
JP6499132B2 (ja) ＦｃＲｎに対する抗体及びその使用
JP6638018B2 (ja) Ｆｃレセプター結合タンパク質
AU2015200004A1 (en) Antibodies against fcrn and use thereof
HK40031845A (en) Antibodies against fcrn and use thereof
HK1160868B (en) Antibodies against fcrn and use thereof
HK1156636B (en) Antibodies against fcrn and use thereof
HK1156636A (en) Antibodies against fcrn and use thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120410

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20120410

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20120926

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20131024

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20140124

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20140131

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20140224

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20140303

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140417

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20141016

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150216

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20150501

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20150703

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160803

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20161117

R150 Certificate of patent or registration of utility model

Ref document number: 6106854

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313113

S531 Written request for registration of change of domicile

Free format text: JAPANESE INTERMEDIATE CODE: R313531

S533 Written request for registration of change of name

Free format text: JAPANESE INTERMEDIATE CODE: R313533

R360 Written notification for declining of transfer of rights

Free format text: JAPANESE INTERMEDIATE CODE: R360

R360 Written notification for declining of transfer of rights

Free format text: JAPANESE INTERMEDIATE CODE: R360

R371 Transfer withdrawn

Free format text: JAPANESE INTERMEDIATE CODE: R371

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313117

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250